NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31

Neurogene Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$24.17+0.92 (+3.96%)

Close on Oct 19, 2026

Market cap: $545.08M
P/E (TTM): –
Dividend yield: –

Neurogene Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	0	0.93	0	–	–	–	–	25	–	–	–	–	–	–
Research & Development	75	61	44	48	39	24	4.42	42	36	28	16	18	7.60	6.05
General & Administrative	28	23	11	9.01	22	17	19	16	15	9.26	5.54	4.30	1.78	1.64
Operating Expenses	103	84	56	57	61	–	71	58	51	38	21	22	9.38	7.68
Operating Income	-103	-83	-56	-57	-61	-34	-71	-33	-51	-38	–	–	–	–
Interest Expense	0.01	0.01	0.01	0.00	–	–	0.00	0.00	0.00	0.00	–	0.45	0.04	0.01
Interest & Investment Income	12	8.47	2.95	1.34	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	13	7.46	–	-0.04	-0.01	0.45	1.52	1.04	0.94	0.64	-0.52	-1.65	0.64	0.01
Merger & Restructuring Charges	–	–	–	1.41	–	0	–	–	–	–	–	–	–	–
Asset Impairment Charges	0.12	0.09	0	–	–	–	–	–	–	–	0	0	0	–
Gain (Loss) on Sale of Assets	–	–	–	-0.12	0	-0.18	-0.01	–	–	–	–	0.01	0.13	–
Pretax Income	-90	-75	-36	-55	-61	-33	-69	-32	-50	-37	-22	-24	-8.73	-7.67
Income Tax Expense	0	0	–	–	–	–	–	–	–	0	0	0	-0.01	0.04
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	-69	-32	-50	-37	–	–	–	–
Net Income	-90	-75	-36	-55	-61	-33	-69	-32	-50	-37	-22	-24	-8.73	-7.71
Net Income to Common	–	–	–	–	–	–	–	–	–	-37	-22	-24	-15	-12
EPS (Basic)(per share)	-4.24	-4.28	–	-5.20	-5.50	-3.20	-12.85	-6.70	-10.70	-9.80	-8.65	-13.75	-247.60	-201.15
EPS (Diluted)(per share)	-4.24	-4.28	–	-5.20	-5.50	-3.20	-12.85	-6.70	-10.70	-9.80	-8.65	-13.75	-247.60	-201.15
Shares Outstanding (Basic, Weighted)(shares)	21	18	–	11	11	10	5.41	4.70	4.69	3.78	2.53	1.73	0.06	0.06
Shares Outstanding (Diluted, Weighted)(shares)	21	18	–	11	11	10	5.41	4.70	4.69	3.78	2.53	1.73	0.06	0.06
EBITDA	-100	-79	-52	-53	-59	-33	-71	-32	-51	–	–	–	–	–
Net Interest Income	–	–	–	1.58	0.02	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -31.4%

Financial strength

Current ratio: 10.64
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 523.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.51
Dividend yield: –